|
V.TLT
|
Yes, the current corporate presentation uses this number as an average ($USD...
|
|
V.TLT
|
I believe in previous corporate presentations Theralase has estimated a cost...
|
|
V.TLT
|
I agree that 80 cents is ridiculously low, but it's based on Dr. Uddin...
|
|
V.TLT
|
Research Capital: Theralase bladder cancer data trending ahead of Keytruda...
|
|
V.TLT
|
If, as Stephen Birch suggests, Theralase does not announce it's...
|
|
V.TLT
|
7 out of 7 pending patients all CR! That really is awesome! This trial really...
|
|
V.TLT
|
I think they're great. If the 3 partial responders at 450 days are...
|
|
V.TLT
|
29 patients have now been evaluated at 450 days. 3 of these were from phase 1...
|
|
V.TLT
|
51 phase 2 patients treated. Of the 43 evaluable patients CR at any time = 60...
|
|
V.TLT
|
It's amazing how many otherwise well informed articles about photodynamic...
|
|
V.TLT
|
NMIBC may not be the only feather in their cap for long. Early 2023 may see a...
|
|
V.TLT
|
Right. Patient 25 should reach 450 days sometime between Thursday, Nov. 24...
|
|
V.HPQ
|
Thanks for that M139. This is a great, mutually beneficial partnership which...
|
|
V.TLT
|
On January 8, 2020, the FDA approved KEYTRUDA for the treatment of patients...
|
|
V.TLT
|
Some posters on this board complain about a lack of communication from...
|
|
V.TLT
|
This recent paper (November 15) from researchers in the People's Republic...
|
|
V.TLT
|
Two weeks to go until the next Theralase update. It's just possible...
|
|
V.TLT
|
The indefatigable Dr. McFarland is working on the ability to provide...
|
|
V.TLT
|
Yes, we don't really know what communication is going on behind the...
|
|
V.TLT
|
Here is what Theralse reported about BTD in the most recent MD&A...
|